FDA cites Multaler et Cie for manufacturing failures and unapproved sunscreen after April 2024 inspection.
What happened
FDA inspected the Multaler et Cie SAS drug manufacturing facility in Argenteuil, France, from April 15 to 17, 2024. FDA found inadequate testing of incoming components, including glycerin and propylene glycol for DEG/EG contamination, laboratory test methods that were not properly validated or controlled, and a purified water system with dead legs and stagnant water. FDA also found YONKA PARIS SOLAR CARE SPF 50 sunscreen marketed as an unapproved new drug because its active ingredient combination is not allowed under the OTC sunscreen monograph.
What FDA found
The company did not adequately test incoming components, including glycerin and propylene glycol, for identity and did not test them for dangerous DEG or EG contamination before use.
21 CFR 211.84(d)(1) and 211.84(d)(2)The company relied on suppliers' certificates of analysis without establishing the reliability of those supplier test results at appropriate intervals.
21 CFR 211.84(d)(2)The company lacked scientifically sound laboratory controls and could not show that its chemical and microbiological test methods were validated or suitable for its drug product.
21 CFR 211.160(b)Microbiological testing lacked positive and negative controls, tested only three organisms instead of USP <62>'s six, and did not test for Burkholderia cepacia complex.
21 CFR 211.160(b)The purified water system used in manufacturing had dead legs and stagnant water and was not designed and maintained for its intended use.
21 CFR 211.63The sunscreen was an unapproved new drug and misbranded because its combination of octocrylene, oxybenzone, avobenzone, and ensulizole is not permitted under the OTC sunscreen monograph M020.
FD&C Act sections 505(a), 301(d), 502(ee), 21 U.S.C. 355(a), 331(d), 352(ee)
What FDA wants
FDA asks the company to respond in writing within 15 working days with corrective actions, including DEG/EG testing and risk assessments, method and water-system remediation plans, and clarification whether it will resume U.S. drug manufacturing. FDA also asks the company to notify FDA before resuming and warns that violations may lead to refusal of U.S. admissions.
Who should pay attention
- brands that use this contract manufacturer for OTC drugs or cosmetics
- companies buying glycerin or propylene glycol-containing products from this facility
- distributors and retailers selling YONKA PARIS sunscreen in the U.S.
This is a summary. Read the original letter on fda.gov.